Veterinary Medicine – Oncology

Masitinib scientific data 22/09/2011 – for veterinary medicine n°3 The Veterinary Journal 21/02/2011 – Results from a preclinical study showing that masitinib has potential as a chemosensitizer Masitinib in Mast Cell Tumor – Phase 3 data 02/11/2010 – Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell…

Overview

AB Science is developing its lead compound masitinib in veterinary medicine.   Since 2008 in Europe and since 2010 in the USA, masitinib is registered in a canine cancer called mast cell tumor, the most common cutaneous cancer in dogs. The drug is marketed by AB Science under the brand Masivet® in Europe and Kinavet in the…